The effectof omega 3 fatty acids supplemention on uterine prostaglandineE2 and aromatase P450 in patients with leiomyoma
Phase 3
Recruiting
- Conditions
- terine Myoma.Leiomyoma of uterus
- Registration Number
- IRCT20130115012146N7
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Age range 40-25 years
Intra molar myomas are less than 50% prominent in the uterine cavity.
Patients with leiomyoma who have been treated for myomas have not used hormonal drugs, including GNRH agonists, progesterone, and so on.
Exclusion Criteria
Patients with uterine obstruction, AUB, PCO and , taking hormonal drugs and
Patients with hormonal disorders
Patients with Polycystic ovary syndrome
Patients with abnormal uterine bleeding
Patients with metabolic disorders
Patients taking hormonal drugs.
Patients with uterine polyps
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Size of myoma. Timepoint: Three months after taking the drug. Method of measurement: sonography.;Number of uterine fibroids. Timepoint: Three months after taking the drug. Method of measurement: sonography.
- Secondary Outcome Measures
Name Time Method PGE2 levels in uterine fluid. Timepoint: Three months after taking the drug. Method of measurement: Measurement in the laboratory.;The amount of aromatase and PGES genes. Timepoint: Three months after taking the drug. Method of measurement: Measurement in the laboratory.